Testing effectiveness (Phase 2)Ended earlyNCT03357224
What this trial is testing
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
Who this might be right for
Lymphoma, T-Cell, CutaneousMycosis Fungoides/Sezary Syndrome
European Organisation for Research and Treatment of Cancer - EORTC 26